Cargando…
P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431169/ http://dx.doi.org/10.1097/01.HS9.0000971456.29068.f6 |
| _version_ | 1785091137442152448 |
|---|---|
| author | Gao, Yan LI, Xue-Ping Wang, Xiao-Xiao Bai, Bing Zhang, Xuan-Ye Lin, Su-Xia He, Yan-Xia Ping, LI-Qin Huang, Cheng LI, Ji-Bin Zhuang, Jia-Ling Huang, Hui-Qiang |
| author_facet | Gao, Yan LI, Xue-Ping Wang, Xiao-Xiao Bai, Bing Zhang, Xuan-Ye Lin, Su-Xia He, Yan-Xia Ping, LI-Qin Huang, Cheng LI, Ji-Bin Zhuang, Jia-Ling Huang, Hui-Qiang |
| author_sort | Gao, Yan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431169 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104311692023-08-17 P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL Gao, Yan LI, Xue-Ping Wang, Xiao-Xiao Bai, Bing Zhang, Xuan-Ye Lin, Su-Xia He, Yan-Xia Ping, LI-Qin Huang, Cheng LI, Ji-Bin Zhuang, Jia-Ling Huang, Hui-Qiang Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431169/ http://dx.doi.org/10.1097/01.HS9.0000971456.29068.f6 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Gao, Yan LI, Xue-Ping Wang, Xiao-Xiao Bai, Bing Zhang, Xuan-Ye Lin, Su-Xia He, Yan-Xia Ping, LI-Qin Huang, Cheng LI, Ji-Bin Zhuang, Jia-Ling Huang, Hui-Qiang P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_full | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_fullStr | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_full_unstemmed | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_short | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_sort | p1140: combination anti-pd1 antibody and rituximab followed by r-chop for newly diagnosed dlbcl in elderly patients: analysis of the phase ii trend trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431169/ http://dx.doi.org/10.1097/01.HS9.0000971456.29068.f6 |
| work_keys_str_mv | AT gaoyan p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT lixueping p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT wangxiaoxiao p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT baibing p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT zhangxuanye p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT linsuxia p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT heyanxia p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT pingliqin p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT huangcheng p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT lijibin p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT zhuangjialing p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT huanghuiqiang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial |